These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35284105)

  • 1. Imatinib-associated skin rash is related to treatment outcome in patients with unresectable and/or metastatic gastrointestinal stromal tumor.
    Zhang M; Li L; Sun H; Tang T; Li Q; Chen L; Chen W
    J Gastrointest Oncol; 2022 Feb; 13(1):117-125. PubMed ID: 35284105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications.
    Park SR; Ryu MH; Ryoo BY; Beck MY; Lee IS; Choi MJ; Lee MW; Kang YK
    Cancer Res Treat; 2016 Jan; 48(1):162-70. PubMed ID: 26323636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
    Kim EJ; Ryu MH; Park SR; Beck MY; Lee WJ; Lee MW; Kang YK
    Oncologist; 2020 Nov; 25(11):e1785-e1793. PubMed ID: 32589310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of imatinib-associated skin rash in a patient with metastatic gastrointestinal stromal tumor: a case report.
    Blay JY
    Clin Sarcoma Res; 2012 Dec; 2(1):23. PubMed ID: 23206868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
    Farag S; van Coevorden F; Sneekes E; Grunhagen DJ; Reyners AKL; Boonstra PA; van der Graaf WT; Gelderblom HJ; Steeghs N
    Eur J Cancer; 2017 Nov; 86():318-325. PubMed ID: 29073582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
    Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
    [No Abstract]   [Full Text] [Related]  

  • 10. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.
    Wang Y; Zhang P; Han Y; Nelson RS; McLeod HL; Tao K; Yuan Y; Zhang M; Xiang H; Zhou H
    Chemotherapy; 2019; 64(4):197-204. PubMed ID: 31955170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).
    Rutkowski P; Bylina E; Lugowska I; Teterycz P; Klimczak A; Streb J; Czarnecka AM; Osuch C
    J Geriatr Oncol; 2018 Sep; 9(5):520-525. PubMed ID: 29602734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
    JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor.
    Hwang JE; Yoon JY; Bae WK; Shim HJ; Cho SH; Chung IJ
    BMC Cancer; 2010 Aug; 10():438. PubMed ID: 20718969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
    Bouché O; Cesne AL; Rios M; Chaigneau L; Italiano A; Duffaud F; Lecomte T; Arsène D; Manfredi S; Aparicio T; Remy S; Isambert N; Collard O; Priou F; Bertucci F; Sambuc R; Bisot-Locard S; Bourges O; Chabaud S; Blay JY
    PLoS One; 2018; 13(9):e0204117. PubMed ID: 30226855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
    Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
    BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
    Blay JY; Rutkowski P
    Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.